The use of intravenous contrast material during a PET/CT exam does not significantly affect the interpretation of the PET component. Contrast-enhanced PET/CT can be used routinely for oncologic imaging, according to researchers from the University of Texas M.D. Anderson Cancer Center in Houston.
The use of intravenous contrast material during a PET/CT exam does not significantly affect the interpretation of the PET component. Contrast-enhanced PET/CT can be used routinely for oncologic imaging, according to researchers from the University of Texas M.D. Anderson Cancer Center in Houston.
IV contrast is generally not used for attenuation correction in whole-body integrated PET/CT. Contrast media elevate the CT Hounsfield units, resulting in an overestimation of PET attenuation factors.
Previous studies looking at this problem have used phantoms or have compared contrast-enhanced CT attenuation-corrected PET images with non-corrected images. Researchers at M.D. Anderson directly compared PET images corrected for attenuation using contrast-enhanced and unenhanced CT images.
Dr. Osama Mawlawi and colleagues performed contrast-enhanced and noncontrast PET/CT exams in nine patients. They quantified the effect of contrast media on standardized uptake values (SUV) by drawing similar regions of interest for the subclavian vein, heart, liver, spleen, and site of malignancy on both CT and corresponding reconstructed PET images (AJR 2006;186:308-319).
Examination of the PET images by two physicians blinded to the CT attenuation correction maps used to reconstruct those images revealed no differences in the clinical interpretations of the PET scans of all nine patients. However, there were differences in reported maximum SUV of the malignancies on PET images reconstructed with contrast-enhanced CT scans compared with the same PET images reconstructed with unenhanced CT scans
The subclavian vein region on the ipsilateral side of contrast administration had the highest increase in CT Hounsfield units with a corresponding increase in SUV. The heart and the site of malignancy also showed an increase in the maximum attenuation value with a corresponding increase in SUV.
The increase in SUV, however, was clinically insignificant in oncologic staging and would not have been misinterpreted as sites of metastases.
"We recommend that a separate contrast-enhanced diagnostic CT not be performed and advocate that IV contrast media could be used routinely when integrated PET/CT is performed to evaluate oncologic patients," the researchers said.
The study will bolster the case for Society of Nuclear Medicine guidelines for PET/CT oncologic imaging to be published in its journal in May. The document lays out a minimum amount of training for nuclear medicine physicians to interpret the CT component of a PET/CT exam - whatever the protocol.
Those guidelines are at odds with requirements from the American College of Radiology, which maintains that the minimum training conditions allow nuclear physicians to interpret only a non-contrast-enhanced CT used for attenuation correction.
For more information from the Diagnostic Imaging archives:
Philips launches speedy time-of-flight PET/CT
Nuclear medicine society serves up online CME
Can MRI-Guided Transurethral Ultrasound Ablation Have an Impact for Localized Prostate Cancer?
December 11th 2023Follow-up MRI imaging one year after transurethral ultrasound ablation revealed approximately 50 percent decreases in prostate volume and median PSA density, according to recently presented research findings at the 2023 Society of Urologic Oncology (SUO) Annual Meeting.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.